The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Fulvestrant as First-Line Treatment for Advanced Breast Cancer

John F. R. Robertson, MD
Published Online: 5:53 PM, Fri December 12, 2014
John F. R. Robertson, MD, professor of surgery, faculty of medicine & health sciences, The University of Nottingham, United Kingdom, discusses overall survival data from the phase II FIRST study, which looked at fulvestrant as first-line therapy for patients with advanced breast cancer.

Clinical Pearls

  • 20-25 years ago, the average survival among patients with advanced breast cancer was 24 months. Now, it is 54.1 months.
  • Overall survival was 5.7 months higher with fulvestrant compared with anastrozole.
  • Benefit for fulvestrant over anastrozole was consistent across subgroups.

<<< Go back to the SABCS conference page

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.